Medicina
Departamento
Josep
Tabernero Caturla
Publicaciones en las que colabora con Josep Tabernero Caturla (93)
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
-
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
Cancer Medicine, Vol. 12, Núm. 11, pp. 12071-12083
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
ESMO Open, Vol. 7, Núm. 3
-
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800
2021
-
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 4, pp. 273-284
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608
2020
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909
-
The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls
Expert Opinion on Biological Therapy, Vol. 20, Núm. 1, pp. 15-22
2019
-
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383
-
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131
-
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
The New England journal of medicine, Vol. 381, Núm. 17, pp. 1632-1643
-
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Cancer Chemotherapy and Pharmacology